Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Natural Products Journal, The
  4. Fast Track Articles
  5. Fast Track Article
image of Is There Any Role for Bach Flowers, Lavender Oil and Hypericum in Psychiatry?

Abstract

Introduction/Objective

Alternative medicine is a term encompassing several approaches proposed for their healing effects instead of conventional medicine. The present narrative review aimed at exploring the possible use of some popular alternative treatments to manage anxiety and depression, with a specific focus on Bach flowers, lavender oil, and Hypericum which are among the most popular alternative remedies in Italy.

Methods

A thorough search was conducted across electronic databases, such as PubMed, Google Scholar, and PsycINFO for English-written papers published in peer-reviewed journals, available in full-text or abstract. The primary keywords included “Alternative medicine”, “Anxiety”, “Depression”, “Bach Flowers”, “Lavender Oil”, and “Hypericum”. Studies were included if they met the following criteria: focus on the Bach flowers, lavender oil, or hypericum, in the treatment or management of anxiety and depression.

Results

The scientific evidence supporting the benefits of Bach flowers for anxiety and depression is still inconclusive, with some studies suggesting potential benefits in reducing anxiety symptoms and other showing no significant effects. Lavender oil has been explored for its potential therapeutic effects on anxiety and depression, but even in this case the overall findings remain controversial due to methodological limitations. St. John’s Wort (or Hypericum) showed some effect in mild to moderate depression, with efficacy comparable to standard antidepressants and fewer side effects, although its use requires careful cautions when prescribed with other drugs.

Conclusion

The overall findings of the present review would indicate that the scientific evidence about the possible usefulness of Bach flowers, lavender oil, and Hypericum is limited. If the effectiveness of Bach flowers is controversial, some potential benefits of lavender oil and Hypericum have been reported, however they need to be replicated and deepened in controlled clinical studies.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/npj/10.2174/0122103155330395241119082537
2025-01-03
2025-04-24

  • From This Site

    /content/journals/npj/10.2174/0122103155330395241119082537
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Cant S. Mainstream Marginality: “‘non-orthodox’” medicine in an “ ‘orthodox’” Health Service. Gabe J. Calnan M. Abingdon, UK Routledge 2009 177 200
    [Google Scholar]
  2. Kaptchuk T.J. Miller F.G. Viewpoint. Acad. Med. 2005 80 3 286 290 10.1097/00001888‑200503000‑00015 15734812
    [Google Scholar]
  3. Veziari Y. Leach M.J. Kumar S. Barriers to the conduct and application of research in complementary and alternative medicine: a systematic review. BMC Complement. Altern. Med. 2017 17 1 166 10.1186/s12906‑017‑1660‑0 28335766
    [Google Scholar]
  4. Hufford D.J. Evaluating complementary and alternative medicine: the limits of science and of scientists. J. Law Med. Ethics 2003 31 2 198 212 10.1111/j.1748‑720X.2003.tb00081.x 12964264
    [Google Scholar]
  5. Power M. Hopayian K. Exposing the evidence gap for complementary and alternative medicine to be integrated into science-based medicine. J. R. Soc. Med. 2011 104 4 155 161 10.1258/jrsm.2011.100271 21502214
    [Google Scholar]
  6. Richard H. Purpose and effectiveness of Complementary and Alternative Medicine (CAM). Glob. J. Med. Med. Sci. 2022 1 1
    [Google Scholar]
  7. Offit P.A. Do you believe in magic? Violence Decline 2013 57
    [Google Scholar]
  8. World Health Organization Traditional, complementary and integrative medicine https://www.who.int/health-topics/traditional-complementary-and-integrative-medicine
    [Google Scholar]
  9. Maizes V. Rakel D. Niemiec C. Integrative medicine and patient-centered care. Explore (NY) 2009 5 5 277 289 10.1016/j.explore.2009.06.008 19733814
    [Google Scholar]
  10. Helms J.M. An overview of medical acupuncture. Altern. Ther. Health Med. 1998 4 3 35 45 9581320
    [Google Scholar]
  11. Clarke S.J. McLachlan A.J. Interaction between complementary and alternate medicine with conventional anti-cancer medicine. Cancer Forum 2020 35 1 18 23 10.3316/informit.854155016595505
    [Google Scholar]
  12. Gorski D. H. “Integrative” medicine: integrating quackery with science-based medicine. MIT Press Scholarship Online Cambridge, MA 2018 10.7551/mitpress/9780262037426.003.0014
    [Google Scholar]
  13. Schulz P. Hede V. Alternative and complementary approaches in psychiatry: beliefs versus evidence. Dialogues Clin. Neurosci. 2018 20 3 207 214 10.31887/DCNS.2018.20.3/pschulz 30581290
    [Google Scholar]
  14. Shapiro S. Rapaport R. The role of complementary and alternative therapies in pediatric diabetes. Endocrinol. Metab. Clin. North Am. 2009 38 4 791 810 10.1016/j.ecl.2009.09.004 19944293
    [Google Scholar]
  15. Halberstein R. DeSantis L. Sirkin A. Padron-Fajardo V. Ojeda-Vaz M. Healing with Bach® Flower essences: testing a complementary therapy. Complement. Health Pract. Rev. 2007 12 1 3 14 10.1177/1533210107300705
    [Google Scholar]
  16. Yang S.W. Koo M. Wang Y.H. The influence of bach rescue remedy on the autonomic response to mental challenge in healthy taiwanese women. Integr. Med. Res. 2015 4 1 84 10.1016/j.imr.2015.04.127
    [Google Scholar]
  17. Fusco S.F.B. Pancieri A.P. Amancio S.C.P. Fusco D.R. Padovani C.R. Minicucci M.F. Spiri W.C. Braga E.M. Efficacy of flower therapy for anxiety in overweight or obese adults: A randomized placebo-controlled clinical trial. J. Altern. Complement. Med. 2021 27 5 416 422 10.1089/acm.2020.0305 33902293
    [Google Scholar]
  18. Salles L. Effect of flower essences in anxious individuals. Acta Paul. Enferm. 2012 25 238 242 10.1590/S0103‑21002012000200013
    [Google Scholar]
  19. Silva S.D.G. Campos T.M.P. Topical use of bach flower remedies in a specific vehicle: A therapeutic innovation. Res. Soc. Dev. 2023 12 6 e12212642029 e12212642029 10.33448/rsd‑v12i6.42029
    [Google Scholar]
  20. Ernst E. Bach flower remedies: a systematic review of randomised clinical trials. Swiss Med. Wkly. 2010 140 3334 w13079 w13079 10.4414/smw.2010.13079 20734279
    [Google Scholar]
  21. Monvoisin R. [Bach flower remedies: a critic of the pseudoscientific, pseudomedicinal concepts and philosophical postures inducted by Dr Bach theory]. Ann. Pharm. Fr. 2005 63 6 416 428 10.1016/S0003‑4509(05)82310‑7 16292234
    [Google Scholar]
  22. Villarreal-Zegarra D. Taype-Roldan A. Use of unproven treatments in mental health: The case of Bach Flowers. Rev. Fac. Med. (Caracas) 2019 67 4 533 10.15446/revfacmed.v67n4.72050
    [Google Scholar]
  23. Cavanagh H.M.A. Wilkinson J.M. Biological activities of Lavender essential oil. Phytother. Res. 2002 16 4 301 308 10.1002/ptr.1103 12112282
    [Google Scholar]
  24. Buchbauer G. Jirovetz L. Jäger W. Dietrich H. Plank C. Aromatherapy: evidence for sedative effects of the essential oil of lavender after inhalation. Z. Naturforsch. C J. Biosci. 1991 46 11-12 1067 1072 10.1515/znc‑1991‑11‑1223 1817516
    [Google Scholar]
  25. Müller W.E. Sillani G. Schuwald A. Friedland K. Pharmacological basis of the anxiolytic and antidepressant properties of Silexan®, an essential oil from the flowers of lavender. Neurochem. Int. 2021 143 104899 10.1016/j.neuint.2020.104899 33181239
    [Google Scholar]
  26. De Sousa D. Hocayen P. Andrade L. Andreatini R. A systematic review of the anxiolytic-like effects of essential oils in animal models. Molecules 2015 20 10 18620 18660 10.3390/molecules201018620 26473822
    [Google Scholar]
  27. Malcolm B.J. Tallian K. Essential oil of lavender in anxiety disorders: Ready for prime time? Ment. Health Clin. 2017 7 4 147 155 10.9740/mhc.2017.07.147 29955514
    [Google Scholar]
  28. Schuwald A.M. Nöldner M. Wilmes T. Klugbauer N. Leuner K. Müller W.E. Lavender oil-potent anxiolytic properties via modulating voltage dependent calcium channels. PLoS One 2013 8 4 e59998 10.1371/journal.pone.0059998 23637742
    [Google Scholar]
  29. Sánchez-Vidaña D.I. Po K.K.T. Fung T.K.H. Chow J.K.W. Lau W.K.W. So P.K. Lau B.W.M. Tsang H.W.H. Lavender essential oil ameliorates depression-like behavior and increases neurogenesis and dendritic complexity in rats. Neurosci. Lett. 2019 701 180 192 10.1016/j.neulet.2019.02.042 30825591
    [Google Scholar]
  30. Malloggi E. Menicucci D. Cesari V. Frumento S. Gemignani A. Bertoli A. Lavender aromatherapy: A systematic review from essential oil quality and administration methods to cognitive enhancing effects. Appl. Psychol. Health Well-Being 2022 14 2 663 690 10.1111/aphw.12310 34611999
    [Google Scholar]
  31. Kasper S. Gastpar M. Müller W.E. Volz H.P. Möller H.J. Dienel A. Schläfke S. Silexan, an orally administered Lavandula oil preparation, is effective in the treatment of ‘subsyndromal’ anxiety disorder: a randomized, double-blind, placebo controlled trial. Int. Clin. Psychopharmacol. 2010 25 5 277 287 10.1097/YIC.0b013e32833b3242 20512042
    [Google Scholar]
  32. Donelli D. Antonelli M. Bellinazzi C. Gensini G.F. Firenzuoli F. Effects of lavender on anxiety: A systematic review and meta-analysis. Phytomedicine 2019 65 153099 10.1016/j.phymed.2019.153099 31655395
    [Google Scholar]
  33. von Känel R. Kasper S. Bondolfi G. Holsboer-Trachsler E. Hättenschwiler J. Hatzinger M. Imboden C. Heitlinger E. Seifritz E. Therapeutic effects of Silexan on somatic symptoms and physical health in patients with anxiety disorders: A meta‐analysis. Brain Behav. 2021 11 4 e01997 10.1002/brb3.1997 33638614
    [Google Scholar]
  34. Grabnar M. Roach M.J. Abd-Elsayed A. Kim C. Impact of lavender on pain and anxiety levels associated with spine procedures. Ochsner J. 2021 21 4 358 363 10.31486/toj.21.0013 34984050
    [Google Scholar]
  35. Kasper S. Müller W.E. Volz H.P. Möller H.J. Koch E. Dienel A. Silexan in anxiety disorders: Clinical data and pharmacological background. World J. Biol. Psychiatry 2018 19 6 412 420 10.1080/15622975.2017.1331046 28511598
    [Google Scholar]
  36. Shammas R.L. Marks C.E. Broadwater G. Le E. Glener A.D. Sergesketter A.R. Cason R.W. Rezak K.M. Phillips B.T. Hollenbeck S.T. The effect of lavender oil on perioperative pain, anxiety, depression, and sleep after microvascular breast reconstruction: A prospective, single-blinded, randomized, controlled trial. J. Reconstr. Microsurg. 2021 37 6 530 540 10.1055/s‑0041‑1724465 33548936
    [Google Scholar]
  37. Bavarsad N.H. Bagheri S. Kourosh-Arami M. Komaki A. Aromatherapy for the brain: Lavender’s healing effect on epilepsy, depression, anxiety, migraine, and Alzheimer’s disease: A review article. Heliyon 2023 9 8 e18492 10.1016/j.heliyon.2023.e18492 37554839
    [Google Scholar]
  38. Woelk H. Schläfke S. A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder. Phytomedicine 2010 17 2 94 99 10.1016/j.phymed.2009.10.006 19962288
    [Google Scholar]
  39. Bartova L. Dold M. Volz H.P. Seifritz E. Möller H.J. Kasper S. Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: Randomized, placebo-controlled trials revisited. Eur. Arch. Psychiatry Clin. Neurosci. 2023 273 1 51 63 10.1007/s00406‑022‑01390‑z 35262795
    [Google Scholar]
  40. Kasper S. An orally administered lavandula oil preparation (Silexan) for anxiety disorder and related conditions: An evidence based review. Int J Psychiatry Clin Pract 2013 17 Suppl 1 15 22 10.3109/13651501.2013.813555
    [Google Scholar]
  41. Kasper S. Volz H.P. Dienel A. Schläfke S. Efficacy of Silexan in mixed anxiety–depression – A randomized, placebo-controlled trial. Eur. Neuropsychopharmacol. 2016 26 2 331 340 10.1016/j.euroneuro.2015.12.002 26718792
    [Google Scholar]
  42. Kim M. Nam E.S. Lee Y. Kang H.J. Effects of lavender on anxiety, depression, and physiological parameters: systematic review and meta-analysis. Asian Nurs. Res. 2021 15 5 279 290 10.1016/j.anr.2021.11.001 34775136
    [Google Scholar]
  43. Firoozeei T.S. Feizi A. Rezaeizadeh H. Zargaran A. Roohafza H.R. Karimi M. The antidepressant effects of lavender (Lavandula angustifolia Mill.): A systematic review and meta-analysis of randomized controlled clinical trials. Complement. Ther. Med. 2021 59 102679 10.1016/j.ctim.2021.102679 33549687
    [Google Scholar]
  44. Jafari-Koulaee A. Elyasi F. Taraghi Z. Ilali E.S. Moosazadeh M. A systematic review of the effects of aromatherapy with lavender essential oil on depression. Cent. Asian J. Glob. Health 2020 9 1 e442 10.5195/cajgh.2020.442 35866093
    [Google Scholar]
  45. Ogata K. Ataka K. Suzuki H. Yagi T. Okawa A. Fukumoto T. Zhang B. Nakata M. Yada T. Asakawa A. Lavender oil reduces depressive mood in healthy individuals and enhances the activity of single oxytocin neurons of the hypothalamus isolated from mice: A preliminary study. Evid. Based Complement. Alternat. Med. 2020 2020 1 5418586 10.1155/2020/5418586 32733584
    [Google Scholar]
  46. Friedland K. Silani G. Schuwald A. Stockburger C. Koch E. Nöldner M. Müller W.E. Neurotrophic properties of silexan, an essential oil from the flowers of lavender-preclinical evidence for antidepressant-like properties. Pharmacopsychiatry 2021 54 1 37 46 10.1055/a‑1293‑8585 33254260
    [Google Scholar]
  47. Marchevsky S. Real-world outcomes of long-term use of silexan in patients with anxiety disorders: A single-centre experience. Int. J. Psychiatry Clin. Pract. 2024 1–4 1 4 10.1080/13651501.2024.2391301 39154289
    [Google Scholar]
  48. Galeotti N. Hypericum perforatum (St John’s wort) beyond depression: A therapeutic perspective for pain conditions. J. Ethnopharmacol. 2017 200 136 146 10.1016/j.jep.2017.02.016 28216196
    [Google Scholar]
  49. Ricciuti S. della Farmacia A. R. Hypericum Perforatum L
  50. Patočka J. The chemistry, pharmacology, and toxicology of the biologically active constituents of the herb Hypericum perforatum L. J. Appl. Biomed. 2003 1 2 61 70 10.32725/jab.2003.010
    [Google Scholar]
  51. Schulz H.U. Schürer M. Bässler D. Weiser D. Investigation of the bioavailability of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin following single and multiple oral dosing of a hypericum extract containing tablet. Arzneimittelforschung 2011 55 1 15 22 10.1055/s‑0031‑1296820 15727160
    [Google Scholar]
  52. Nicolussi S. Drewe J. Butterweck V. Meyer zu Schwabedissen H.E. Clinical relevance of St. John’s wort drug interactions revisited. Br. J. Pharmacol. 2020 177 6 1212 1226 10.1111/bph.14936 31742659
    [Google Scholar]
  53. Bennett D.A. Jr Phun L. Polk J.F. Voglino S.A. Zlotnik V. Raffa R.B. Neuropharmacology of St. John’s Wort ( Hypericum ). Ann. Pharmacother. 1998 32 11 1201 1208 10.1345/aph.18026 9825087
    [Google Scholar]
  54. Czigle S. Nagy M. Mladěnka P. Tóth J. OEMONOM. Pharmacokinetic and pharmacodynamic herb-drug interactions—part I. Herbal medicines of the central nervous system. PeerJ 2023 11 e16149 10.7717/peerj.16149 38025741
    [Google Scholar]
  55. Canenguez Benitez J.S. Hernandez T.E. Sundararajan R. Sarwar S. Arriaga A.J. Khan A.T. Matayoshi A. Quintanilla H.A. Kochhar H. Alam M. Mago A. Hans A. Benitez G.A. Advantages and disadvantages of using St. John’s Wort as a treatment for depression. Cureus 2022 14 9 e29468 10.7759/cureus.29468 36299970
    [Google Scholar]
  56. Beijamini V. Andreatini R. Effects of Hypericum perforatum and paroxetine on rat performance in the elevated T-maze. Pharmacol. Res. 2003 48 2 199 207 10.1016/S1043‑6618(03)00097‑5 12798673
    [Google Scholar]
  57. Bukhari I.A. Dar A. Behavioral profile of Hypericum perforatum (St. John’s Wort) extract. A comparison with standard antidepressants in animal models of depression. Eur. Rev. Med. Pharmacol. Sci. 2013 17 8 1082 1089 23661522
    [Google Scholar]
  58. Can Ö. Öztürk Y. Özkay Ü. Effects of insulin and St. John’s Wort treatments on anxiety, locomotory activity, depression, and active learning parameters of streptozotocin-diabetic rats. Planta Med. 2011 77 18 1970 1976 10.1055/s‑0031‑1280129 21858758
    [Google Scholar]
  59. Fiebich B.L. Knörle R. Appel K. Kammler T. Weiss G. Pharmacological studies in an herbal drug combination of St. John’s Wort (Hypericum perforatum) and passion flower (Passiflora incarnata): In vitro and in vivo evidence of synergy between Hypericum and Passiflora in antidepressant pharmacological models. Fitoterapia 2011 82 3 474 480 10.1016/j.fitote.2010.12.006 21185920
    [Google Scholar]
  60. Flausino O.A. Jr Zangrossi H. Jr Salgado J.V. Viana M.B. Effects of acute and chronic treatment with Hypericum perforatum L. (LI 160) on different anxiety-related responses in rats. Pharmacol. Biochem. Behav. 2002 71 1-2 251 257 10.1016/S0091‑3057(01)00665‑7 11812530
    [Google Scholar]
  61. Husain G.M. Chatterjee S.S. Singh P.N. Kumar V. Beneficial effect of Hypericum perforatum on depression and anxiety in a type 2 diabetic rat model. Acta Pol. Pharm. 2011 68 6 913 918 22125957
    [Google Scholar]
  62. Khalil H.M.A. Mahmoud D.B. El-Shiekh R.A. Bakr A.F. Boseila A.A. Mehanna S. Naggar R.A. Eliwa H.A. Antidepressant and cardioprotective effects of self-nanoemulsifying self-nanosuspension loaded with Hypericum Perforatum on post-myocardial infarction depression in rats. AAPS PharmSciTech 2022 23 7 243 10.1208/s12249‑022‑02387‑6 36028598
    [Google Scholar]
  63. Sevastre-Berghian A.C. Toma V.A. Sevastre B. Hanganu D. Vlase L. Benedec D. Oniga I. Baldea I. Olteanu D. Moldovan R. Decea N. Filip G.A. Clichici S.V. Characterization and biological effects of Hypericum extracts on experimentally-induced - Anxiety, oxidative stress and inflammation in rats. J. Physiol. Pharmacol. Off. J. Pol. Physiol. Soc. 2018 69 5 10.26402/jpp.2018.5.13 30683830
    [Google Scholar]
  64. Murck H. Atypical depression and related illnesses--neurobiological principles for their treatment with Hypericum extract Wien Med Wochenschr 2002 152 15-16 398 403 10.1046/j.1563‑258X.2002.02061.x
    [Google Scholar]
  65. Linde K. Berner M.M. Kriston L. St John’s wort for major depression. Cochrane Libr. 2008 2008 4 CD000448 10.1002/14651858.CD000448.pub3 18843608
    [Google Scholar]
  66. RT Davidson Jonathan. Effect of Hypericum Perforatum (St John’s Wort) in major depressive disorder: A randomized controlled trial. JAMA 2002 287 14 1807 1814 10.1001/jama.287.14.1807
    [Google Scholar]
  67. Sarris J. Kavanagh D.J. Kava and St. John’s Wort: Current evidence for use in mood and anxiety disorders. J. Altern. Complement. Med. 2009 15 8 827 836 10.1089/acm.2009.0066 19614563
    [Google Scholar]
  68. Schrader E. Meier B. Brattström A. Hypericum treatment of mild–moderate depression in a placebo–controlled study. A prospective, double–blind, randomized, placebo–controlled, multicentre study. Hum. Psychopharmacol. Clin. Exp. 1998 13 3 163 169 10.1002/(SICI)1099‑1077(199804)13:3<163::AID‑HUP5>3.0.CO;2‑I
    [Google Scholar]
  69. Volz H.-P. Controlled clinical trials of Hypericum extracts in depressed patients - An overview. Pharmacopsychiatry 1997 30 S 2 72 76 10.1055/s‑2007‑979522
    [Google Scholar]
  70. Walling A.D. Hypericum in the treatment of patients with depression. Am. Fam. Physician 2000 61 10 3103 3104
    [Google Scholar]
  71. Whiskey E. Werneke U. Taylor D. A systematic review and meta-analysis of Hypericum perforatum in depression: A comprehensive clinical review. Int. Clin. Psychopharmacol. 2001 16 5 239 252 10.1097/00004850‑200109000‑00001 11552767
    [Google Scholar]
  72. Behnke K. Jensen G.S. Graubaum H.J. Gruenwald J. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression. Adv. Ther. 2002 19 1 43 52 10.1007/BF02850017 12008860
    [Google Scholar]
  73. Ng Q.X. Venkatanarayanan N. Ho C.Y.X. Clinical use of Hypericum perforatum (St John’s wort) in depression: A meta-analysis. J. Affect. Disord. 2017 210 211 221 10.1016/j.jad.2016.12.048 28064110
    [Google Scholar]
  74. Bilia A.R. Gallori S. Vincieri F.F. St. John’s wort and depression. Life Sci. 2002 70 26 3077 3096 10.1016/S0024‑3205(02)01566‑7 12008092
    [Google Scholar]
  75. Brenner R. Azbel V. Madhusoodanan S. Pawlowska M. Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: A double-blind, randomized pilot study. Clin. Ther. 2000 22 4 411 419 10.1016/S0149‑2918(00)89010‑4 10823363
    [Google Scholar]
  76. Zheng Y. Cui Y. A meta-analysis on the efficacy and safety of St John’s wort extract in depression therapy in comparison with selective serotonin reuptake inhibitors in adults. Neuropsychiatr. Dis. Treat. 2016 12 1715 1723 10.2147/NDT.S106752 27468236
    [Google Scholar]
  77. Kholghi G. Arjmandi-Rad S. Zarrindast M.R. Vaseghi S. St. Johnʼs wort (Hypericum perforatum) and depression: What happens to the neurotransmitter systems? Naunyn Schmiedebergs Arch. Pharmacol. 2022 395 6 629 642 10.1007/s00210‑022‑02229‑z 35294606
    [Google Scholar]
  78. Zirak N. Shafiee M. Soltani G. Mirzaei M. Sahebkar A. Hypericum perforatum in the treatment of psychiatric and neurodegenerative disorders: Current evidence and potential mechanisms of action. J. Cell. Physiol. 2019 234 6 8496 8508 10.1002/jcp.27781 30461013
    [Google Scholar]
  79. Ayati Z. Sarris J. Chang D. Emami S.A. Rahimi R. Herbal medicines and phytochemicals for obsessive–compulsive disorder. Phytother. Res. 2020 34 8 1889 1901 10.1002/ptr.6656 32124509
    [Google Scholar]
  80. Camfield D.A. Sarris J. Berk M. Nutraceuticals in the treatment of Obsessive Compulsive Disorder (OCD): A review of mechanistic and clinical evidence. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011 35 4 887 895 10.1016/j.pnpbp.2011.02.011 21352883
    [Google Scholar]
  81. Kobak K.A. Taylor L.V.H. Bystritsky A. Kohlenberg C.J. Greist J.H. Tucker P. Warner G. Futterer R. Vapnik T. St John's wort versus placebo in obsessive-compulsive disorder: Results from a double-blind study. Int. Clin. Psychopharmacol. 2005 20 6 299 304 10.1097/00004850‑200511000‑00003 16192837
    [Google Scholar]
  82. Taylor L.H. Kobak K.A. An open-label trial of St. John’s Wort (Hypericum perforatum) in obsessive-compulsive disorder. J. Clin. Psychiatry 2000 61 8 575 578 10.4088/JCP.v61n0806 10982200
    [Google Scholar]
  83. Kasper S. Anghelescu I.-G. Szegedi A. Dienel A. Kieser M. Placebo controlled continuation treatment with Hypericum Extract WS 5570 after recovery from a mild or moderate depressive episode. Wien. Med. Wochenschr. 2007 157 13–14 362 366 10.1007/s10354‑007‑0441‑7
    [Google Scholar]
  84. Martinez B. Kasper S. Ruhrmann S. Möller H.J. Hypericum in the treatment of seasonal affective disorders. J. Geriatr. Psychiatry Neurol. 1994 7 1_suppl Suppl. 1 29 33 10.1177/089198879400701s09 7857504
    [Google Scholar]
  85. Wan H. Chen Y. Effects of antidepressive treatment of Saint John’s wort extract related to autonomic nervous function in women with irritable bowel syndrome. Int. J. Psychiatry Med. 2010 40 1 45 56 10.2190/PM.40.1.d 20565044
    [Google Scholar]
  86. Peterson B. Nguyen H.St. John’s Wort. StatPearls. StatPearls Publishing Treasure Island, FL 2024
    [Google Scholar]
  87. Ernst E. Pittler M.H. Alternative therapy bias. Nature 1997 385 6616 480 480 10.1038/385480c0 9020351
    [Google Scholar]
  88. Singh S. Ernst E. Trick or Treatment: the undeniable facts about alternative medicine. W. W. Norton Company New York, United States 2008
    [Google Scholar]
  89. Purohit M.P. Zafonte R.D. Sherman L.M. Davis R.B. Giwerc M.Y. Shenton M.E. Yeh G.Y. Neuropsychiatric symptoms and expenditure on complementary and alternative medicine. J. Clin. Psychiatry 2015 76 7 e870 e876 10.4088/JCP.13m08682 26231014
    [Google Scholar]
  90. Gorski D.H. Novella S.P. Clinical trials of integrative medicine: Testing whether magic works? Trends Mol. Med. 2014 20 9 473 476 10.1016/j.molmed.2014.06.007 25150944
    [Google Scholar]
  91. Ravindran A.V. Balneaves L.G. Faulkner G. Ortiz A. McIntosh D. Morehouse R.L. Ravindran L. Yatham L.N. Kennedy S.H. Lam R.W. MacQueen G.M. Milev R.V. Parikh S.V. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the management of adults with major depressive disorder: Section 5. Complementary and alternative medicine treatments. Can. J. Psychiatry 2016 61 9 576 587 10.1177/0706743716660290 27486153
    [Google Scholar]
  92. Sarris J. Ravindran A. Yatham L.N. Marx W. Rucklidge J.J. McIntyre R.S. Akhondzadeh S. Benedetti F. Caneo C. Cramer H. Cribb L. de Manincor M. Dean O. Deslandes A.C. Freeman M.P. Gangadhar B. Harvey B.H. Kasper S. Lake J. Lopresti A. Lu L. Metri N.J. Mischoulon D. Ng C.H. Nishi D. Rahimi R. Seedat S. Sinclair J. Su K.P. Zhang Z.J. Berk M. Clinician guidelines for the treatment of psychiatric disorders with nutraceuticals and phytoceuticals: The world federation of societies of biological psychiatry (WFSBP) and Canadian network for mood and anxiety treatments (canmat) taskforce. World J. Biol. Psychiatry 2022 23 6 424 455 10.1080/15622975.2021.2013041 35311615
    [Google Scholar]
/content/journals/npj/10.2174/0122103155330395241119082537
Loading

  • Article Type:     Review Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test